Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

Completed · Not applicable · Has a placebo group

Conditions studied: HIV Infections

In brief

The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.

Key facts

Study ID

NCT00706550

Run by

US Department of Veterans Affairs

People needed

107

Starts

2008-10-01

Expected to finish

2012-09-01

Last updated by the study team

2014-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infected
• CD4 count >200
• no acute illness
• no pneumococcal vaccination within 3 years
• naive to treatment or if previously on treatment, no antiretroviral treatment for at least 6 months
• willingness to start antiretroviral treatment as recommended by current guidelines

You may not qualify if…

• prior pneumococcal vaccination within 3 years
• prior AIDS diagnosis based on opportunistic disease
• acute illness

Where it is running

• Michael E DeBakey VA Medical Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.